FDA Approves ABIRATERONE ACETATE — Rising Pharma Holdings, Inc.

Rising Pharma Holdings, Inc. announced the FDA’s February 25, 2019, approval of its oral Abiraterone Acetate drug, positioning the company to compete within the androgen signaling inhibitor market. This approval is expected to drive market share by lowering the cost of care, thereby exerting pricing pressure on branded counterparts in the treatment of castration-resistant prostate cancer.